ClinicalTrials.gg
CompletedNCT01430559Updated Dec 31, 2020Results posted

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

An interventional study of Meloxicam and Placebo in Osteoarthritis of the Knee, sponsored by Pfizer. Completed at 25 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Pfizer · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Osteoarthritis, Knee by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis, Knee · Pfizer.

Enrollment
8th of 17
408 · median 200
Started
2011
with 1 other
No phase
Only one
of the 17
Registered
11th of 17
by date

Among the 17 studies in Osteoarthritis, Knee by Pfizer, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is the only one with no phase, and was the 11th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 17 studies in Osteoarthritis, Knee by Pfizer are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Osteoarthritis, Knee by Pfizer, or all of them as a file.
02

Study summary

This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis in this population.

Read the detailed description

To validate culturally the WOMAC tool in mainland China and observe the different response of meloxicam and placebo in a patient population with osteoarthritis of the knee

03

Conditions studied

  • Osteoarthritis of the Knee

Keywords

  • Validation of the WOMAC in Chinese subjects with osteoarthritis of the knee
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are required to meet the following criteria to be eligible for Randomization into this study:

  • Male or female Chinese subjects, 18-75 years of age;
  • Subjects must have a diagnosis of OA of the index knee based on American College of Rheumatology criteria with X ray confirmation (a Kellgren Lawrence x ray grade of greater than or equal to 2) (Kellgren J. \& Lawrence J, 1957)
  • Subjects must have have an NRS and a WOMAC pain sub scale score of 4 at Screening and at Baseline based on four daily diary entries

Exclusion criteria

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

  • History of other disease that may involve the index (painful) knee including inflammatory joint diseases or have had recent surgical intervention on the knee.
  • Diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving the first dose of study medication. History of or active gastrointestinal disease (eg, inflammatory bowel disease), a chronic or acute renal or hepatic disorder, or a significant coagulation defect.
  • Signs and symptoms of cardiac disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
408 participants (actual)

Study arms

  • Other
    Meloxicam

    Drug: Meloxicam

  • Placebo comparator
    Placebo

    2 Placebo capsules once a day for 12 weeks

    Drug: Placebo

Interventions

  • 7.5mg x2 once a day for 12 weeks

    Also known as: Mobic

  • DrugPlacebo

    Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.

06

What researchers measure

Primary outcomes

  1. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 1 by Using a Paper Worksheet and a Personalized Electronic LogPad System (E-diary)

    The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

    Time frame: Screening 1 (Visit 1: Days -21 to -14)

  2. WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 2 by Using E-diary

    The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

    Time frame: Screening 2 (Visit 2: Days -14 to -10)

  3. WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Baseline by Using E-diary

    The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

    Time frame: Baseline (Day 1)

  4. WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Week 12 by Using E-diary

    The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

    Time frame: Visit 8 (Week 12)

  5. Change From Baseline in WOMAC Pain Subscale Scores at Week 12

    WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in WOMAC Subscale and Average Scores at Weeks 2, 4, 8 and 12

    The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. Change from baseline was calculated for each WOMAC subscale (pain, stiffness, physical function) and WOMAC average score.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  2. Change From Baseline in WOMAC Pain Subscale Items at Weeks 2, 4, 8 and 12

    WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. Change from baseline in two of the WOMAC pain subscale items: pain when walking on a flat surface, and pain when going up or down stairs were calculated.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  3. Percentage of Participants With Cumulative Reduction From Baseline in WOMAC Pain Subscale at Week 12

    WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. WOMAC pain subscale response rates at Week 12 were shown for the reductions from Baseline of greater than (\>) 0%, 10% to 90% (in steps of 10%).

    Time frame: Baseline and Week 12

  4. Percentage of Participants With at Least 30% and 50% Reduction From Baseline in the WOMAC Pain Subscale at Weeks 2, 4, 8, and 12

    WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  5. Change From Baseline in Patient Global Assessment of Osteoarthritis (PGAO) at Weeks 2, 4, 8 and 12

    PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 scores with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  6. Percentage of Participants With >=2 Points Improvement in PGAO From Baseline at Weeks 2, 4, 8, and 12

    PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 grades with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis. The treatment response of an improvement of \>=2 points from Baseline in PGAO were summarized.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  7. Change From Baseline in Short-Form 36 Health Survey (SF-36) Domain Scores and Component Scores at Week 12

    The SF-36 is a self-administered questionnaire that measures each of the following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary (including physical functioning, role-physical, bodily pain and general health) and mental component summary (including vitality, social functioning, role-emotional and mental health). Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status.

    Time frame: Baseline and Week 12

  8. Percentage of Participants With Change From Baseline in EuroQoL-5 Domains (EQ-5D) Level at Week 12

    The EQ-5D is a generic measure of health related quality of life. The EQ-5D has 5 items that assess the level of difficulty (none \[score of 1\], some/moderate \[score of 2\], extreme \[score of 3\]) respondents report for 5 health status domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The change from Baseline (decrease by 2, 1, 0, -1 and -2) at Week 12 in each of the 5 health status domains were summarized.

    Time frame: Baseline and Week 12

  9. Change From Baseline in Weekly Average Pain Score in the Index Knee Using 11-point Numeric Rating Scale (NRS) at Weeks 2, 4, 8 and 12

    Daily average knee pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated worse pain. The participants described their pain in the index knee during the past 24 hours by choosing the appropriate number from 0 to 10.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

07

Results

Posted Dec 31, 2020

Participant flow

A total of 24 centers in mainland China recruited study participants, starting from 24 Oct 2011 to 14 Dec 2012.

Participant flow — Overall Study
MilestonePlaceboMeloxicam 15 mg
Started146147
Treated143144
Completed126135
Not completed2012
Withdrew: Adverse event73
Withdrew: Entry criteria not met11
Withdrew: Lost to follow-up10
Withdrew: Medication error10
Withdrew: Withdrawal by subject32
Withdrew: Protocol violation10
Withdrew: Other33
Withdrew: Randomized, not treated33

Outcome measures

PrimaryThe Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 1 by Using a Paper Worksheet and a Personalized Electronic LogPad System (E-diary)

The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

Time frame:
Screening 1 (Visit 1: Days -21 to -14)
Reported as:
Mean · units on a scale
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 1 by Using a Paper Worksheet and a Personalized Electronic LogPad System (E-diary)
units on a scaleOA ParticipantsHealthy Participants
Pain subscale (paper worksheet)5.7 ± 1.47—
Stiffness subscale (paper worksheet)5.3 ± 1.94—
Physical function subscale (paper worksheet)5.7 ± 1.56—
Total (paper worksheet)135.9 ± 35.59—
Pain subscale (e-dary)5.7 ± 1.470.1 ± 0.22
Stiffness subscale (e-diary)5.3 ± 2.000.1 ± 0.31
Physical function subscale (e-diary)5.7 ± 1.560.0 ± 0.14
Total (e-diary)136.0 ± 35.920.8 ± 3.66
PrimaryWOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 2 by Using E-diary

The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

Time frame:
Screening 2 (Visit 2: Days -14 to -10)
Reported as:
Mean · units on a scale
WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 2 by Using E-diary
units on a scaleOA Participants
Pain subscale score5.6 ± 1.46
Stiffness subscale score5.4 ± 1.76
Physical function subscale score5.8 ± 1.52
Total score136.6 ± 35.38
PrimaryWOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Baseline by Using E-diary

The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

Time frame:
Baseline (Day 1)
Reported as:
Mean · units on a scale
WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Baseline by Using E-diary
units on a scalePlaceboMeloxicam 15 mg
Pain subscale score6.0 ± 1.296.0 ± 1.32
Stiffness subscale score5.7 ± 1.565.6 ± 1.65
Physical function subscale score6.1 ± 1.326.1 ± 1.22
Total score145.0 ± 31.05144.8 ± 29.57
PrimaryWOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Week 12 by Using E-diary

The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.

Time frame:
Visit 8 (Week 12)
Reported as:
Mean · units on a scale
WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Week 12 by Using E-diary
units on a scalePlaceboMeloxicam 15 mg
Pain subscale score4.4 ± 2.053.6 ± 1.90
Stiffness subscale score4.2 ± 2.263.5 ± 1.96
Physical function subscale score4.5 ± 2.083.7 ± 1.87
Total score106.6 ± 49.7088.7 ± 44.45
PrimaryChange From Baseline in WOMAC Pain Subscale Scores at Week 12

WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in WOMAC Pain Subscale Scores at Week 12
units on a scalePlaceboMeloxicam 15 mg
Change From Baseline in WOMAC Pain Subscale Scores at Week 12-1.24 (-1.71 to -0.77)-2.06 (-2.53 to -1.58)
Statistical analysis
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from analysis of covariance (ANCOVA, repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.82 · 95% CI -1.20 to -0.43
SecondaryChange From Baseline in WOMAC Subscale and Average Scores at Weeks 2, 4, 8 and 12

The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. Change from baseline was calculated for each WOMAC subscale (pain, stiffness, physical function) and WOMAC average score.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in WOMAC Subscale and Average Scores at Weeks 2, 4, 8 and 12
units on a scalePlaceboMeloxicam 15 mg
Pain subscale (Week 2)-0.76 (-1.15 to -0.36)-1.12 (-1.52 to -0.73)
Pain subscale (Week 4)-1.18 (-1.60 to -0.76)-1.53 (-1.95 to -1.11)
Pain subscale (Week 8)-1.31 (-1.74 to -0.87)-1.82 (-2.26 to -1.39)
Pain subscale (Week 12)-1.24 (-1.71 to -0.77)-2.06 (-2.53 to -1.58)
Stiffness subscale (Week 2)-0.78 (-1.16 to -0.39)-1.11 (-1.49 to -0.72)
Stiffness subscale (Week 4)-1.14 (-1.58 to -0.71)-1.34 (-1.78 to -0.90)
Stiffness subscale (Week 8)-1.23 (-1.66 to -0.79)-1.70 (-2.14 to -1.25)
Stiffness subscale (Week 12)-1.20 (-1.67 to -0.72)-1.86 (-2.34 to -1.39)
Physical function subscale (Week 2)-0.77 (-1.19 to -0.36)-1.21 (-1.63 to -0.80)
Physical function subscale (Week 4)-1.18 (-1.62 to -0.75)-1.53 (-1.96 to -1.09)
Physical function subscale (Week 8)-1.31 (-1.74 to -0.88)-1.82 (-2.26 to -1.38)
Physical function subscale (Week 12)-1.25 (-1.73 to -0.77)-2.06 (-2.54 to -1.58)
Average score (Week 2)-0.77 (-1.15 to -0.39)-1.15 (-1.54 to -0.77)
Average score (Week 4)-1.17 (-1.60 to -0.75)-1.47 (-1.90 to -1.04)
Average score (Week 8)-1.29 (-1.71 to -0.86)-1.78 (-2.22 to -1.35)
Average score (Week 12)-1.23 (-1.70 to -0.76)-2.00 (-2.47 to -1.52)
Statistical analysis
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0103 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.37 · 95% CI -0.65 to -0.09
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0295 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.35 · 95% CI -0.67 to -0.04
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0041 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.52 · 95% CI -0.87 to -0.17
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.82 · 95% CI -1.20 to -0.43
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0369 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.33 · 95% CI -0.64 to -0.02
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.2642 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.20 · 95% CI -0.54 to 0.15
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0140 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.47 · 95% CI -0.84 to -0.10
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0009 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.67 · 95% CI -1.06 to -0.28
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0017 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.44 · 95% CI -0.72 to -0.17
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0328 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.35 · 95% CI -0.66 to -0.03
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0043 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.51 · 95% CI -0.86 to -0.16
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.81 · 95% CI -1.19 to -0.43
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0051 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.38 · 95% CI -0.65 to -0.12
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0593 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.30 · 95% CI -0.61 to 0.01
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0046 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.50 · 95% CI -0.84 to -0.16
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.76 · 95% CI -1.14 to -0.39
SecondaryChange From Baseline in WOMAC Pain Subscale Items at Weeks 2, 4, 8 and 12

WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. Change from baseline in two of the WOMAC pain subscale items: pain when walking on a flat surface, and pain when going up or down stairs were calculated.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in WOMAC Pain Subscale Items at Weeks 2, 4, 8 and 12
units on a scalePlaceboMeloxicam 15 mg
Walking on flat surface (Week 2)-0.51 (-0.92 to -0.10)-1.13 (-1.54 to -0.71)
Walking on flat surface (Week 4)-1.04 (-1.50 to -0.59)-1.61 (-2.07 to -1.15)
Walking on flat surface (Week 8)-1.17 (-1.63 to -0.71)-1.87 (-2.33 to -1.41)
Walking on flat surface (Week 12)-1.05 (-1.53 to -0.56)-1.97 (-2.46 to -1.48)
Going up or down stairs (Week 2)-1.00 (-1.40 to -0.60)-1.35 (-1.75 to -0.94)
Going up or down stairs (Week 4)-1.34 (-1.76 to -0.93)-1.74 (-2.16 to -1.32)
Going up or down stairs (Week 8)-1.53 (-2.00 to -1.07)-2.09 (-2.55 to -1.62)
Going up or down stairs (Week 12)-1.34 (-1.83 to -0.86)-2.43 (-2.91 to -1.94)
Statistical analysis
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0002 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.62 · 95% CI -0.94 to -0.30
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0015 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.57 · 95% CI -0.92 to -0.22
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0003 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.70 · 95% CI -1.08 to -0.32
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.93 · 95% CI -1.34 to -0.51
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0363 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.35 · 95% CI -0.67 to -0.02
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0311 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.39 · 95% CI -0.75 to -0.04
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0057 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.55 · 95% CI -0.94 to -0.16
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -1.08 · 95% CI -1.52 to -0.64
SecondaryPercentage of Participants With Cumulative Reduction From Baseline in WOMAC Pain Subscale at Week 12

WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. WOMAC pain subscale response rates at Week 12 were shown for the reductions from Baseline of greater than (\>) 0%, 10% to 90% (in steps of 10%).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Cumulative Reduction From Baseline in WOMAC Pain Subscale at Week 12
percentage of participantsPlaceboMeloxicam 15 mg
>0% reduction53.175.7
Greater than or equal to (>=) 10% reduction46.267.4
>=20% reduction37.158.3
>=30% reduction29.449.3
>=40% reduction22.443.8
>=50% reduction16.134.0
>=60% reduction10.524.3
>=70% reduction7.712.5
>=80% reduction4.26.3
>=90% reduction2.13.5
SecondaryPercentage of Participants With at Least 30% and 50% Reduction From Baseline in the WOMAC Pain Subscale at Weeks 2, 4, 8, and 12

WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 30% and 50% Reduction From Baseline in the WOMAC Pain Subscale at Weeks 2, 4, 8, and 12
percentage of participantsPlaceboMeloxicam 15 mg
>=30% reduction (Week 2)17.4822.92
>=30% reduction (Week 4)30.0736.81
>=30% reduction (Week 8)34.9745.14
>=30% reduction (Week 12)29.3749.31
>=50% reduction (Week 2)4.909.03
>=50% reduction (Week 4)9.0914.58
>=50% reduction (Week 8)13.2924.31
>=50% reduction (Week 12)16.0834.03
Statistical analysis
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.2373 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.42 · 95% CI 0.79 to 2.55
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.2069 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.38 · 95% CI 0.84 to 2.26
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0680 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.56 · 95% CI 0.97 to 2.53
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0005 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.41 · 95% CI 1.47 to 3.94
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.1736 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.94 · 95% CI 0.75 to 5.01
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.1496 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.72 · 95% CI 0.82 to 3.59
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0171 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.12 · 95% CI 1.14 to 3.93
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0004 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.77 · 95% CI 1.57 to 4.89
SecondaryChange From Baseline in Patient Global Assessment of Osteoarthritis (PGAO) at Weeks 2, 4, 8 and 12

PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 scores with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient Global Assessment of Osteoarthritis (PGAO) at Weeks 2, 4, 8 and 12
units on a scalePlaceboMeloxicam 15 mg
Week 2-0.27 (-0.39 to -0.15)-0.45 (-0.57 to -0.33)
Week 4-0.37 (-0.50 to -0.23)-0.53 (-0.66 to -0.39)
Week 8-0.34 (-0.46 to -0.23)-0.52 (-0.64 to -0.40)
Week 12-0.43 (-0.58 to -0.28)-0.62 (-0.78 to -0.47)
Statistical analysis
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0027 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.19 · 95% CI -0.31 to -0.07
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0308 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.16 · 95% CI -0.30 to -0.01
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0060 · Least squares mean difference: -0.18 · 95% CI -0.31 to -0.05
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0076 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.20 · 95% CI -0.34 to -0.05
SecondaryPercentage of Participants With >=2 Points Improvement in PGAO From Baseline at Weeks 2, 4, 8, and 12

PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 grades with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis. The treatment response of an improvement of \>=2 points from Baseline in PGAO were summarized.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=2 Points Improvement in PGAO From Baseline at Weeks 2, 4, 8, and 12
percentage of participantsPlaceboMeloxicam 15 mg
Week 22.804.86
Week 46.2911.81
Week 85.596.25
Week 128.3913.19
Statistical analysis
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.2843 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.13 · 95% CI 0.53 to 8.50
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.1050 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.05 · 95% CI 0.86 to 4.87
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.7861 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.16 · 95% CI 0.40 to 3.32
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.1873 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.71 · 95% CI 0.77 to 3.78
SecondaryChange From Baseline in Short-Form 36 Health Survey (SF-36) Domain Scores and Component Scores at Week 12

The SF-36 is a self-administered questionnaire that measures each of the following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary (including physical functioning, role-physical, bodily pain and general health) and mental component summary (including vitality, social functioning, role-emotional and mental health). Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Short-Form 36 Health Survey (SF-36) Domain Scores and Component Scores at Week 12
units on a scalePlaceboMeloxicam 15 mg
General health4.60 (1.93 to 7.28)5.98 (3.29 to 8.67)
Physical functioning6.95 (3.73 to 10.16)12.88 (9.65 to 16.12)
Role physical5.79 (1.74 to 9.84)13.95 (9.89 to 18.02)
Bodily pain7.51 (4.44 to 10.58)14.87 (11.78 to 17.96)
Vitality5.03 (2.56 to 7.50)7.08 (4.61 to 9.55)
Social functioning6.06 (2.60 to 9.51)12.02 (8.55 to 15.49)
Role emotional4.65 (0.26 to 9.04)10.52 (6.11 to 14.93)
Mental health4.50 (2.13 to 6.87)5.07 (2.71 to 7.43)
Mental component aggregate2.19 (0.74 to 3.65)3.14 (1.67 to 4.60)
Physical component aggregate2.65 (1.36 to 3.94)5.21 (3.92 to 6.51)
Statistical analysis
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.3738 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 1.38 · 95% CI -1.67 to 4.42
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0028 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 5.94 · 95% CI 2.07 to 9.80
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0002 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 8.16 · 95% CI 3.95 to 12.38
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = <0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 7.36 · 95% CI 4.10 to 10.63
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.2124 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 2.05 · 95% CI -1.18 to 5.27
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0050 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 5.96 · 95% CI 1.82 to 10.10
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0093 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 5.87 · 95% CI 1.46 to 10.28
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.7274 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 0.57 · 95% CI -2.66 to 3.81
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.2819 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 0.94 · 95% CI -0.78 to 2.67
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0001 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: 2.57 · 95% CI 1.27 to 3.86
SecondaryPercentage of Participants With Change From Baseline in EuroQoL-5 Domains (EQ-5D) Level at Week 12

The EQ-5D is a generic measure of health related quality of life. The EQ-5D has 5 items that assess the level of difficulty (none \[score of 1\], some/moderate \[score of 2\], extreme \[score of 3\]) respondents report for 5 health status domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The change from Baseline (decrease by 2, 1, 0, -1 and -2) at Week 12 in each of the 5 health status domains were summarized.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Change From Baseline in EuroQoL-5 Domains (EQ-5D) Level at Week 12
percentage of participantsPlaceboMeloxicam 15 mg
Mobility (decrease by 2)00
Mobility (decrease by 1)2.80.7
Mobility (decrease by 0)79.766.0
Mobility (decrease by -1)14.028.5
Mobility (decrease by -2)00
Self-care (decrease by 2)00
Self-care (decrease by 1)3.54.2
Self-care (decrease by 0)67.855.6
Self-care (decrease by -1)25.235.4
Self-care (decrease by -2)00
Usual activities (decrease by 2)00
Usual activities (decrease by 1)0.72.8
Usual activities (decrease by 0)81.163.2
Usual activities (decrease by -1)14.729.2
Usual activities (decrease by -2)00
Pain/discomfort (decrease by 2)00
Pain/discomfort (decrease by 1)2.12.1
Pain/discomfort (decrease by 0)77.667.4
Pain/discomfort (decrease by -1)15.425.0
Pain/discomfort (decrease by -2)1.40.7
Anxiety/depression (decrease by 2)0.70
Anxiety/depression (decrease by 1)7.76.3
Anxiety/depression (decrease by 0)72.067.4
Anxiety/depression (decrease by -1)14.720.8
Anxiety/depression (decrease by -2)1.40.7
Statistical analysis
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0014 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.60 · 95% CI 1.45 to 4.66
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.1080 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.51 · 95% CI 0.91 to 2.48
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0119 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 2.06 · 95% CI 1.17 to 3.62
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.0887 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.62 · 95% CI 0.93 to 2.83
  • Placebo vs Meloxicam 15 mg · Regression, Logistic · p = 0.2466 (P-value and 95% confidence interval for odds ratio were calculated from logistic regression model (including baseline value and treatment group as factors) for binary data for comparison of meloxicam group versus placebo.) · Odds ratio (or): 1.37 · 95% CI 0.80 to 2.33
SecondaryChange From Baseline in Weekly Average Pain Score in the Index Knee Using 11-point Numeric Rating Scale (NRS) at Weeks 2, 4, 8 and 12

Daily average knee pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated worse pain. The participants described their pain in the index knee during the past 24 hours by choosing the appropriate number from 0 to 10.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Weekly Average Pain Score in the Index Knee Using 11-point Numeric Rating Scale (NRS) at Weeks 2, 4, 8 and 12
units on a scalePlaceboMeloxicam 15 mg
Week 2-0.67 (-1.00 to -0.34)-0.97 (-1.30 to -0.64)
Week 4-1.11 (-1.51 to -0.70)-1.42 (-1.83 to -1.01)
Week 8-1.31 (-1.78 to -0.85)-1.76 (-2.22 to -1.29)
Week 12-1.43 (-1.94 to -0.91)-2.06 (-2.57 to -1.55)
Statistical analysis
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0367 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.30 · 95% CI -0.58 to -0.02
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0652 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.32 · 95% CI -0.65 to 0.02
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0200 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.44 · 95% CI -0.81 to -0.07
  • Placebo vs Meloxicam 15 mg · ANCOVA · p = 0.0016 (P-value and 95% confidence interval for least squares mean difference were calculated from ANCOVA (repeated measures) model with baseline value and treatment group as fixed effects, and study site as a random effect.) · Least squares mean difference: -0.63 · 95% CI -1.02 to -0.24

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/143 (1.4%)0/143 (0%)
Meloxicam 15 mg—0/144 (0%)0/144 (0%)
OA Participants Not Randomized—0/63 (0%)0/63 (0%)
OA Participants Randomized But Not Treated—0/6 (0%)0/6 (0%)
Healthy Participants—0/52 (0%)0/52 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboMeloxicam 15 mgOA Participants Not RandomizedOA Participants Randomized But Not TreatedHealthy Participants
Angina unstableCardiac disorders1/1430/1440/630/60/52
AstheniaGeneral disorders1/1430/1440/630/60/52
Haemoglobin decreasedInvestigations1/1430/1440/630/60/52
Platelet count decreasedInvestigations1/1430/1440/630/60/52
Red blood cell count decreasedInvestigations1/1430/1440/630/60/52
Weight decreasedInvestigations1/1430/1440/630/60/52
White blood cell count decreasedInvestigations1/1430/1440/630/60/52
Decreased appetiteMetabolism and nutrition disorders1/1430/1440/630/60/52
RashSkin and subcutaneous tissue disorders1/1430/1440/630/60/52

Baseline characteristics

Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study medication.

Age, Customized
Age, Customized(Participants)PlaceboMeloxicam 15 mgTotal
26 to 35 years112
36 to 45 years41216
46 to 55 years434487
56 to 65 years6160121
66 to 75 years342761
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMeloxicam 15 mgTotal
Female106122228
Male372259
08

Study locations

25 sites
  • Anhui Province Hospital
    Hefei, Anhui 230001, China
  • The Third Affiliated Hospital Of Sun Yat-sen University
    Guangzhou, Guangdong 510630, China
  • The First Affiliated Hospital of Shantou Medical Collage
    Shantou City, Guangdong 515041, China
  • Rheumatology Department, The first Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Rheumatology Department, The First Hospital of China Medical University
    Shenyang, Liaoning, China
  • QiLu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Liaocheng People's Hospital/Orthopaedics
    Liaocheng, Shandong 252000, China
  • Department of Immunology and Rheumatology, Qingdao Municipal Hospital
    Qingdao, Shandong 266011, China
  • Department of Immunology and Rheumatology,Qingdao Municipal Hospital
    Qingdao, Shandong 266011, China
  • Xijing Hospital, The Fourth Military Medical University
    Xi'an, Shanxi 710032, China
  • Department of Orthopedics, West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Department of Rheumatology and Immunology,West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
  • Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • Sichuan Provincial People's Hospital, Rheumatology
    Chengdu, Sichuan 610072, China
  • China-Japan Friendship Hospital/Rheumatology Department
    Beijing, 100029, China
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Li Zhanguo
    Beijing, 100044, China
  • Rheumatology and Immunology Department, Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
  • Peking Union Medical College Hospital, Orthopaedics
    Beijing, 100730, China
  • Renji Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, 200001, China
  • Rheumatology and Immunology Department, Shanghai Changzheng Hospital
    Shanghai, 200003, China
  • Zhongshan Hospital Fudan University, Rheumatology Department
    Shanghai, 200032, China
  • Department of Infectious Diseases & Immunology, Tianjin Medical University General Hospital
    Tianjin, 300052, China
09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Mar 2013, 17 months.

Results were first posted in Dec 2020, 7 years 9 months after primary completion.

Of 140 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 17 months is close to that.

Counting every sponsor, half of 1,251 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2011
First posted
Sep 8, 2011
StartActual
Oct 24, 2011
Primary completionActual
Mar 27, 2013
CompletionActual
Mar 27, 2013
Results first posted
Dec 31, 2020
Last update
Dec 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01430559
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 8, 2011
Start date
Oct 24, 2011
Primary completion
Mar 27, 2013
Completion
Mar 27, 2013
Results posted
Dec 31, 2020
Last update
Dec 31, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion